

I. AMENDMENTS

In the claims:

Please cancel claims 15 to 19, 21, 22, 25, 26 and 33 to 38.

Please amend claims 20 and 23, as follows by deleting the stricken-through material and inserting the underlined material as follows. After entry of the amendments, the pending claims will recite as follows.

20. (Currently Amended) A pharmaceutical composition comprising the composition of Claim 27, ~~at least one recombinant MVA virus according to Claim 15~~ and a pharmaceutically acceptable carrier or diluent.
23. (Currently Amended) A method for mounting an immune response in an animal to Dengue virus infection, the method comprising administering to the animal the ~~pharmaceutical~~ composition of Claim ~~20~~ 27.
24. (Original) The method according to Claim 23, wherein the animal is a human.
27. (Previously Amended) A composition comprising a first and second component, wherein the first component is a vector comprising more than one DNA sequence selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigen, a DNA sequence encoding a Dengue virus serotype 2 antigen, a DNA sequence encoding a Dengue virus serotype 3 antigen, or a DNA sequence encoding a Dengue virus serotype 4 antigen and wherein the more than one DNA sequences are under the transcriptional control of a T7 RNA polymerase promoter and the second component is a recombinant Modified Vaccinia Ankara (MVA) virus comprising a DNA sequence encoding T7 RNA polymerase.
28. (Original) The composition of Claim 27, wherein the vector of the first component is a plasmid.
32. (Original) A cell containing the composition of claim 27.